DeepX Health Welcomes Renowned Researcher and Entrepreneur Andre Esteva to Advisory Board

DeepX Health, a teledermatology and AI diagnostic companyspecializing in the early detection of skin cancer, proudly announces theappointment of Andre Esteva as its newest advisory board member.


"DeepX'sapproach to commercializing AI-based skin diagnostics is unique," said Andre Esteva. "Theirsubstantial international market traction indicates an insightful way topenetrate this very large and very complex space. It’s noteworthy to see thesubstantial progress achieved through revenue, rather than solely relying oninvestment capital.”


With a distinguished background in pioneering medical AIsolutions, Esteva brings a wealth of experience from his tenure as Head ofMedical AI at Salesforce Research and various roles at esteemed institutionsincluding Google Research, Sandia National Labs, and GE Healthcare. He currentlyserves as the Founder and CEO of Artera AI, a pioneer in medical AI.


Esteva's illustrious career has been marked by hisgroundbreaking research focusing on medical AI diagnostics and precisionmedicine. Notably, he was the co-lead author of one of the seminal papers ondeep learning algorithms for skin cancer detection published in Nature in2017.  His publications have been on thecovers of prestigious journals such as Nature and Nature Medicine, and havebeen featured in other top journals including Cell, The Lancet, and NeurIPS.His work has received widespread attention from media outlets such as The WallStreet Journal, Fortune, BBC, and The Economist, solidifying his reputation asa thought leader in the field.


A Stanford alumn, Esteva earned his PhD in ArtificialIntelligence, specializing in deep learning and computer vision applied tohealthcare. Prior to this, he achieved undergraduate degrees with highesthonors in Electrical Engineering and Pure Mathematics from UT-Austin, where hewas honored as Engineering Valedictorian.


On the Board of Advisors of DeepX Health, Esteva will contributeto the company's mission to revolutionize skin healthcare through cutting-edgeAI technologies, building upon his proven track record of innovation andleadership in the industry.


Christian Horn, founder and CEO of DeepX Health, said, "Weare thrilled to welcome Andre Esteva to DeepX Health's advisory board. Hisextensive experience and groundbreaking contributions to AI diagnostics will beinvaluable as we continue to innovate and expand our teledermatology anddiagnostic solutions.”

About Skin Cancer

Skin cancer is the most prevalent cancer worldwide. In theUnited States alone, it is estimated that about 5 million adults are treatedfor skin cancer each year. Approximately 1/5 people in the US will develop skincancer in their lifetime, and nearly 20 Americans die from melanoma each day.The most prevalent types of skin cancer are melanoma, basal cell carcinoma andsquamous cell carcinoma. Early detection is critical to improve thesurvivability of skin cancer.

About DeepX Health

DeepX Health is a teledermatology and skin cancerdiagnostics company working to enable early skin cancer diagnosis byintegrating device technology, AI, and teledermatology. Our DermoSightdermatoscope is designed for integration with our AI diagnostics algorithm (indevelopment), empowered by our proprietary “Optical Biopsy” technology.


Our DermoSight service has facilitated over 200,000consultations in Boots pharmacies and primary care locations across Europe. DermoSightis FDA cleared and ready for U.S market entry, demonstrating our commitment toadvancing teledermatology for the benefits of patients and practitionerseverywhere.​


For more information, please visit

For all enquiries, please contact

April 2, 2024

Telehealth Pioneer Paul Johnson Joins DeepX Health Advisory Board

Read more

July 11, 2023

DeepX Health’s DermoSight featured on BBC

Read more

July 10, 2023

DeepX Health’s DermoSight at NHS event on 12 July

Read more

June 6, 2023

DeepX Diagnostics Inc.'s DermoSight Receives FDA Clearance for Teledermatology Screening of Suspect Skin Cancer Lesions

Read more

June 2, 2023

DeepX Health’s Skin Cancer Teledermoscopy Services Now in Jersey

Read more

November 29, 2021

New Board Advisor to DeepX Health

Read more

March 30, 2021

New Head of Product at DeepX Health

Read more

March 15, 2021

DeepX Health selected to present at Nordic Life Science Days

Read more

December 15, 2020

Pharmacy Screening Demonstrates Great Efficiency and Potential for Cost Reductions

Read more

October 23, 2020

Primary Care Setting Pilot Launched with NHS

Read more

October 14, 2020

DeepX Health to Present at the 8th World Congress of Teledermatology, Imaging and Artificial Intelligence for Skin Diseases

Read more

September 30, 2020

ScreenCancer Awarded Support for Diagnostic Triage Algorithm-Project

Read more

January 8, 2020

DeepX Health to participate at the 7th Annual Dermatology Summit in San Francisco

Read more

December 13, 2019

DeepX Health to present at Digital Health World Congress in London

Read more

December 3, 2019

DeepX Health participate in the DxPx Conference

Read more

December 1, 2019

ScreenCancer approved for first round of Horizon 2020 programme

Read more